VKTX Stock Price, Viking Therapeutics Inc Quote, Chart

Market Summary

USD79.89+0.28

Market Closed

0.35%

VKTX Alerts

2 major insider sales recently.

VKTX Stock Price

View Fullscreen

VKTX RSI Chart

VKTX Valuation

Market Cap

8.8B

Price/Earnings (Trailing)

-94

Price/Free Cashflow

-160.56

VKTX Price/Sales (Trailing)

VKTX Profitability

Return on Equity

-10.04%

Return on Assets

-9.69%

Free Cashflow Yield

-0.62%

VKTX Fundamentals

VKTX Earnings

Earnings (TTM)

-93.7M

Earnings Growth (Yr)

-40.06%

Earnings Growth (Qtr)

-11.18%

Breaking Down VKTX Revenue

Last 7 days

0.0%

Last 30 days

4.1%

Last 90 days

225.1%

Trailing 12 Months

248.2%

How does VKTX drawdown profile look like?

VKTX Financial Health

Current Ratio

29.48

VKTX Investor Care

Shares Dilution (1Y)

40.73%

Diluted EPS (TTM)

-0.93

Tracking the Latest Insider Buys and Sells of Viking Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	zante greg	sold	-4,986,010	74.69	-66,756	chief financial officer
May 03, 2024	zante greg	acquired	166,285	4.85519	34,249	chief financial officer
May 01, 2024	mancini marianna	acquired	1,740,580	6.18486	281,425	chief operating officer
May 01, 2024	mancini marianna	sold	-22,136,500	78.6585	-281,425	chief operating officer
Mar 27, 2024	lian brian	acquired	-	-	221,667	president & ceo
Mar 27, 2024	mancini marianna	acquired	-	-	31,667	chief operating officer
Mar 27, 2024	zante greg	sold (taxes)	-1,384,280	83.34	-16,610	chief financial officer
Mar 27, 2024	mancini marianna	sold (taxes)	-1,384,280	83.34	-16,610	chief operating officer
Mar 27, 2024	lian brian	sold (taxes)	-12,830,000	83.34	-153,948	president & ceo
Mar 27, 2024	zante greg	acquired	-	-	31,667	chief financial officer

Which funds bought or sold VKTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	Inspire Investing, LLC	reduced	-79.69	-42,117	358,832	0.04%
May 07, 2024	ASSETMARK, INC	new	-	62,566	62,566	-%
May 07, 2024	THOROUGHBRED FINANCIAL SERVICES, LLC	new	-	1,061,000	1,061,000	0.10%
May 07, 2024	SEI INVESTMENTS CO	added	77.65	3,276,460	3,756,340	0.01%
May 07, 2024	Lisanti Capital Growth, LLC	reduced	-84.47	-2,050,750	4,443,580	1.08%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	91.53	20,667,100	23,445,200	-%
May 07, 2024	Quantum Private Wealth, LLC	added	9.69	4,754,420	5,994,770	2.22%
May 07, 2024	VERUS CAPITAL PARTNERS, LLC	new	-	221,400	221,400	0.02%
May 07, 2024	ClariVest Asset Management LLC	new	-	768,340	768,340	0.08%
May 07, 2024	Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.	new	-	42,204,800	42,204,800	6.51%

Are Funds Buying or Selling VKTX?

Are funds buying VKTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VKTX

No. of Funds

VKTX Alerts

2 major insider sales recently.

Unveiling Viking Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	viking global investors lp	5.1%	5,145,112	SC 13G/A
Feb 13, 2024	vanguard group inc	5.38%	5,381,904	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	7.6%	7,605,867	SC 13G
Jan 24, 2024	state street corp	5.73%	5,732,990	SC 13G/A
Jan 12, 2024	millennium management llc	0.4%	403,556	SC 13G/A
Nov 02, 2023	viking global investors lp	5.9%	5,858,532	SC 13G
Apr 10, 2023	fmr llc	-	0	SC 13G
Mar 30, 2023	ligand pharmaceuticals inc	4.6%	3,616,077	SC 13D/A
Feb 14, 2023	arrowmark colorado holdings llc	0.02%	15,931	SC 13G/A

Recent SEC filings of Viking Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 03, 2024	144	Notice of Insider Sale Intent
May 03, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 01, 2024	144	Notice of Insider Sale Intent
Apr 25, 2024	10-Q	Quarterly Report
Apr 24, 2024	8-K	Current Report
Apr 05, 2024	DEFA14A	DEFA14A
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	ARS	ARS
Mar 27, 2024	4	Insider Trading

Peers (Alternatives to Viking Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	17.66%	-8.12%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.45%	-26.53%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-4.99%	-13.89%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-1.56%	-17.34%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.34%	-51.87%	-12.3	9.79	394.93%	39.61%
AXSM	3.6B	251.0M	6.53%	-0.98%	-12.15	14.35	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-0.20%	-12.84%	24.28	4.35	85.90%	-14.05%
NVAX	625.6M	983.7M	4.30%	-38.12%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	-0.70%	291.81%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-5.85%	11.55%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-3.32%	88.89%	-0.24	2.14	-13.45%	66.37%

Viking Therapeutics Inc News

Latest updates

Viking Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	162.6%	968	368	383	401	151	169	167	182	195	211	224	238	250	257	264	271	277	284	290	294	300
Current Assets	163.1%	966	367	381	399	149	167	165	180	193	211	224	238	250	256	263	271	276	284	289	294	299
Cash Equivalents	252.3%	196	56.00	37.00	70.00	18.00	37.00	29.00	16.00	12.00	26.00	11.00	9.00	17.00	29.00	4.00	19.00	15.00	8.00	31.00	19.00	14.00
Liabilities	67.5%	34.00	20.00	14.00	15.00	17.00	23.00	15.00	16.00	13.00	9.00	11.00	13.00	13.00	12.00	10.00	9.00	9.00	7.00	7.00	6.00	6.00
Current Liabilities	71.3%	33.00	19.00	13.00	13.00	16.00	22.00	14.00	15.00	11.00	9.00	11.00	13.00	13.00	12.00	10.00	9.00	9.00	7.00	6.00	6.00	5.00
Shareholder's Equity	168.0%	934	348	368	386	134	145	151	165	182	202	213	225	237	244	254	262	268	277	283	288	295
Retained Earnings	-7.2%	-405	-377	-353	-330	-311	-292	-272	-256	-239	-223	-210	-197	-182	-168	-157	-147	-138	-128	-121	-115	-107
Additional Paid-In Capital	82.8%	1,341	734	729	725	453	445	432	430	428	426	424	423	420	413	411	410	407	406	405	404	402
Shares Outstanding	10.1%	110	100	100	100	78.00	78.00	77.00	77.00	77.00	77.00	77.00	76.00	75.00	73.00	72.00	72.00	72.00	72.00	-	-	-
Float	-	-	-	-	94.00	-	-	-	196	-	-	-	417	-	-	-	470	-	-	-	535	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	65.2%	-6,134	-17,640	-19,658	-11,435	-24,643	-10,926	-13,499	-13,442	-10,530	-12,350	-10,926	-13,434	-10,876	-5,486	-5,323	-6,666	-4,302	-11,743	-3,398	-6,459	-3,152
Share Based Compensation	95.6%	7,981	4,080	4,481	4,620	3,569	2,156	1,940	2,220	2,357	1,433	1,599	1,491	1,577	1,043	1,474	1,648	1,652	976	811	922	1,034
Cashflow From Investing	-1386.7%	-459,792	35,733	-12,534	-204,483	2,198	7,260	26,894	18,980	1,619	27,410	13,617	3,560	-6,627	30,269	-9,634	9,780	11,152	-11,061	15,154	10,979	-7,609
Cashflow From Financing	322260.1%	606,037	188	-74.00	267,078	4,184	10,749	10.00	-1,590	-5,006	47.00	-256	1,898	5,191	464	37.00	416	33.00	229	73.00	260	325
Buy Backs	-	-	-	-	-	-	-	-	1,674	5,121	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VKTX Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 0	$ 0
Operating expenses:
Research and development	24,103	11,008
General and administrative	9,970	9,529
Total operating expenses	34,073	20,537
Loss from operations	(34,073)	(20,537)
Other income (expense):
Amortization of financing costs	(28)	(28)
Interest income, net	6,745	1,034
Total other income, net	6,717	1,006
Net loss	(27,356)	(19,531)
Other comprehensive loss, net of tax:
Unrealized gain (loss) on securities	(1,125)	501
Foreign currency translation loss	(85)	(17)
Comprehensive loss	$ (28,566)	$ (19,047)
Basic net loss per common share	$ (0.26)	$ (0.25)
Diluted net loss per common share	$ (0.26)	$ (0.25)
Weighted-average shares used to compute basic net loss per share	103,457,305	78,351,826
Weighted-average shares used to compute diluted net loss per share	103,457,305	78,351,826

VKTX Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 195,579	$ 55,516
Short-term investments – available for sale	767,397	306,563
Prepaid clinical trial and preclinical study costs	2,716	2,624
Prepaid expenses and other current assets	643	2,522
Total current assets	966,335	367,225
Right-of-use assets	1,052	1,126
Deferred financing costs	98	106
Deposits	33	33
Total assets	967,518	368,490
Current liabilities:
Accounts payable	5,225	7,512
Other accrued liabilities	27,220	11,299
Lease liability, current	329	324
Total current liabilities	32,774	19,135
Lease liability, net of current portion	852	936
Total long-term liabilities	852	936
Total liabilities	33,626	20,071
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.00001 par value: 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 110,228,869 shares issued and outstanding at March 31, 2024 and 100,113,770 shares issued and outstanding at December 31, 2023	1	1
Treasury stock at cost, no shares at March 31, 2024 and 2,193,251 shares at December 31, 2023	0	(6,795)
Additional paid-in capital	1,340,789	733,546
Accumulated deficit	(405,299)	(377,944)
Accumulated other comprehensive loss	(1,599)	(389)
Total stockholders’ equity	933,892	348,419
Total liabilities and stockholders’ equity	$ 967,518	$ 368,490

About Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃƒÅ¸), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃƒÅ¸ for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

CEO	Dr. Brian Lian Ph.D.
WEBSITE	vikingtherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	22

Viking Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Viking Therapeutics Inc? What does VKTX stand for in stocks?

VKTX is the stock ticker symbol of Viking Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Viking Therapeutics Inc (VKTX)?

As of Tue May 07 2024, market cap of Viking Therapeutics Inc is 8.78 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VKTX stock?

You can check VKTX's fair value in chart for subscribers.

What is the fair value of VKTX stock?

You can check VKTX's fair value in chart for subscribers. The fair value of Viking Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Viking Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VKTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Viking Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether VKTX is over valued or under valued. Whether Viking Therapeutics Inc is cheap or expensive depends on the assumptions which impact Viking Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VKTX.